Neoleukin Therapeutics Overview
Neoleukin Therapeutics (NLTX) has a ROE of -51.17%, above the Healthcare sector average of -100.59%.
Get informed when a big investor buys or sells
+ Follow-51.17%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Neoleukin Therapeutics (NLTX) currently reports a ROE of -51.17%. That is above the Healthcare sector average of -100.59%. Use the charts on this page to explore Neoleukin Therapeutics's ROE history and peer comparisons.
Neoleukin Therapeutics's ROE of -51.17% is higher than the Healthcare sector average of -100.59%. That is roughly 49.1% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but Neoleukin Therapeutics's current -51.17% should be judged against Healthcare norms (sector average: -100.59%) and against NLTX's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of -51.17%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is -100.59%. From there, open related valuation or income-statement pages for Neoleukin Therapeutics, and consider following NLTX for alerts when major investors trade the stock.
Neoleukin Therapeutics is classified in the Healthcare sector. On ROE, it currently shows -51.17% versus a sector average near -100.59%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing NLTX with unrelated industries.
